Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial

Andre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, Michael Robertson, Irit Avivi, Jacob M. Rowe, Raoul Herbrecht, Achiel Van Hoof, Lei Zhang, Sherri Cicero, Tommy Fu, Thomas Witzig

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Patients with mantle cell lymphoma (MCL) generally respond to first-line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL-001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long-term efficacy follow-up of the prospective phase II MCL-001 study (N = 134), including new exploratory analyses with baseline Ki-67 (MIB1), a biological marker of tumour proliferation. With longer follow-up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression-free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki-67. Ki-67 data in 81/134 MCL-001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki-67-expressing groups, yet lower Ki-67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post-bortezomib.

Original languageEnglish
Pages (from-to)496-503
Number of pages8
JournalBritish Journal of Haematology
Volume170
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Mantle-Cell Lymphoma
Cell Proliferation
Neoplasms
Survival
Mitoxantrone
Anthracyclines
Immunologic Factors
Tumor Biomarkers
lenalidomide
Cyclophosphamide
Disease-Free Survival
Safety
Recurrence
Drug Therapy

Keywords

  • Efficacy
  • Ki-67
  • Lenalidomide
  • Mantle cell lymphoma
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. / Goy, Andre; Kalayoglu Besisik, Sevgi; Drach, Johannes; Ramchandren, Radhakrishnan; Robertson, Michael; Avivi, Irit; Rowe, Jacob M.; Herbrecht, Raoul; Van Hoof, Achiel; Zhang, Lei; Cicero, Sherri; Fu, Tommy; Witzig, Thomas.

In: British Journal of Haematology, Vol. 170, No. 4, 01.08.2015, p. 496-503.

Research output: Contribution to journalArticle

Goy, A, Kalayoglu Besisik, S, Drach, J, Ramchandren, R, Robertson, M, Avivi, I, Rowe, JM, Herbrecht, R, Van Hoof, A, Zhang, L, Cicero, S, Fu, T & Witzig, T 2015, 'Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial', British Journal of Haematology, vol. 170, no. 4, pp. 496-503. https://doi.org/10.1111/bjh.13456
Goy, Andre ; Kalayoglu Besisik, Sevgi ; Drach, Johannes ; Ramchandren, Radhakrishnan ; Robertson, Michael ; Avivi, Irit ; Rowe, Jacob M. ; Herbrecht, Raoul ; Van Hoof, Achiel ; Zhang, Lei ; Cicero, Sherri ; Fu, Tommy ; Witzig, Thomas. / Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. In: British Journal of Haematology. 2015 ; Vol. 170, No. 4. pp. 496-503.
@article{3ab603e59a5442c1a26f44db1b37ee2c,
title = "Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial",
abstract = "Patients with mantle cell lymphoma (MCL) generally respond to first-line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL-001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long-term efficacy follow-up of the prospective phase II MCL-001 study (N = 134), including new exploratory analyses with baseline Ki-67 (MIB1), a biological marker of tumour proliferation. With longer follow-up, lenalidomide showed a 28{\%} overall response rate [ORR; 8{\%} complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression-free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki-67. Ki-67 data in 81/134 MCL-001 patients showed similar ORRs in both low (<30{\%} or <50{\%}) versus high (≥30{\%} or ≥50{\%}) Ki-67-expressing groups, yet lower Ki-67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post-bortezomib.",
keywords = "Efficacy, Ki-67, Lenalidomide, Mantle cell lymphoma, Safety",
author = "Andre Goy and {Kalayoglu Besisik}, Sevgi and Johannes Drach and Radhakrishnan Ramchandren and Michael Robertson and Irit Avivi and Rowe, {Jacob M.} and Raoul Herbrecht and {Van Hoof}, Achiel and Lei Zhang and Sherri Cicero and Tommy Fu and Thomas Witzig",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/bjh.13456",
language = "English",
volume = "170",
pages = "496--503",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial

AU - Goy, Andre

AU - Kalayoglu Besisik, Sevgi

AU - Drach, Johannes

AU - Ramchandren, Radhakrishnan

AU - Robertson, Michael

AU - Avivi, Irit

AU - Rowe, Jacob M.

AU - Herbrecht, Raoul

AU - Van Hoof, Achiel

AU - Zhang, Lei

AU - Cicero, Sherri

AU - Fu, Tommy

AU - Witzig, Thomas

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Patients with mantle cell lymphoma (MCL) generally respond to first-line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL-001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long-term efficacy follow-up of the prospective phase II MCL-001 study (N = 134), including new exploratory analyses with baseline Ki-67 (MIB1), a biological marker of tumour proliferation. With longer follow-up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression-free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki-67. Ki-67 data in 81/134 MCL-001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki-67-expressing groups, yet lower Ki-67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post-bortezomib.

AB - Patients with mantle cell lymphoma (MCL) generally respond to first-line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL-001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long-term efficacy follow-up of the prospective phase II MCL-001 study (N = 134), including new exploratory analyses with baseline Ki-67 (MIB1), a biological marker of tumour proliferation. With longer follow-up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression-free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki-67. Ki-67 data in 81/134 MCL-001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki-67-expressing groups, yet lower Ki-67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post-bortezomib.

KW - Efficacy

KW - Ki-67

KW - Lenalidomide

KW - Mantle cell lymphoma

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84938549108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938549108&partnerID=8YFLogxK

U2 - 10.1111/bjh.13456

DO - 10.1111/bjh.13456

M3 - Article

VL - 170

SP - 496

EP - 503

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -